Bluebird Bio bluebirdbio.com


Public list: BIO 2016 (619) Pharma Startups (4732) Cancer Therapeutics (1137)

Bluebird Bio, formerly Genetix Pharmaceuticals, is developing gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of treatments for diseases with few or no clinical options. The company's approach uses stem cells harvested from the patient's bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to...Show all

Bluebird Bio, formerly Genetix Pharmaceuticals, is developing gene therapies for severe genetic disorders. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of treatments for d...Show all

Company (IPO / Went public)

Phone: 339-499-9300

Fax:

60 Binney St.

Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Bluebird Bio $349.2M Aug 6, 2018
See all 3 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Bluebird Bio Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 15 investors

Competitors

Company Status Description Investors

Kite Pharma

Foster City, California, United States
AcquiredKite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide...Show allLogin to see details

Audentes Therapeutics

San Francisco, California, United States
IPO / Went publicAudentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).Login to see details
See all 3 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Jun 08, 2012 Oct 17, 2017 Patent
Gene therapy methods Sep 23, 2011 Oct 10, 2017 Patent
Therapeutic retroviral vectors for gene therapy Sep 23, 2011 Jun 30, 2015 Patent
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Sep 16, 2014 Jun 23, 2015 Patent
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Jun 08, 2012 Oct 14, 2014 Patent
See all 21 patents